Amplia Therapeutics Ltd Sustainability Reports
Amplia Therapeutics Limited is an Australian clinical-stage biopharmaceutical company focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors. Its pipeline includes drug candidates targeted for the treatment of cancer and chronic fibrotic diseases.
Sector: Manufacturing
Country: Australia
Exchange: Australian Securities Exchange
FIGI: BBG005M56XJ3
4 reports from 2019 to 2025
